Literature DB >> 16458330

Distributions of five common point mutants in the human tracheal-bronchial epithelium.

Hiroko Sudo1, Xiao-Cheng Li-Sucholeiki, Luisa A Marcelino, Amanda N Gruhl, Helmut Zarbl, James C Willey, William G Thilly.   

Abstract

The mutations C742T, G746T, G747T in the TP53 gene and G35T in the KRAS gene have been repeatedly found in sectors of human tumors by direct DNA sequencing. The mutation G508A in the HPRT1 gene has been repeatedly found among peripheral T lymphocytes by clonal expansion under selective conditions. To discover if these mutations also occur frequently in normal tissues from which tumors arise, we have developed and validated allele-specific mismatch amplification mutation assays (MAMA) for each mutation. Reconstruction experiments demonstrated linearity in the range of 9-3000 mutant alleles among 3 x 10(6) wild-type alleles. The cumulative distributions of all negative controls established robust detection limits (P<0.05) of 34-125 mutants per 10(6) copies assayed depending on the mutation. One hundred and seventy-seven micro-anatomical samples of approximately (0.5-6)x10(6) tracheal-bronchial epithelial cells from nine non-smokers were assayed representing en toto the equivalent of approximately 1.6 human bronchial trees to the fifth bifurcation. Statistically significant mutant copy numbers were found in 257 of 463 assays. Clusters of mutant copies ranged from 10 to 1000 in 239/257 positive samples. As all five point mutations were detected at mutant fractions of >10(-5) in two or more lungs, we infer that they are mutational hotspots generated in lung epithelial stem cells. As the cancer-associated mutations did not differ in cluster size distribution from the HPRT1 mutation, we infer that none of the mutations conferred a growth advantage to somatic heterozygous clusters or maintenance turnover units. Specific mutants appeared in very large copy numbers, 1000-35,000, in 18/257 positive assays. Various hypotheses to account for the observed cluster size distributions are offered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458330     DOI: 10.1016/j.mrfmmm.2005.12.008

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  6 in total

1.  Metakaryotic stem cell lineages in organogenesis of humans and other metazoans.

Authors:  Elena V Gostjeva; Vera Koledova; Aoy Tomita-Mitchell; Michael Mitchell; Mary A Goetsch; Susannah Varmuza; Janna N Fomina; Firouz Darroudi; William G Thilly
Journal:  Organogenesis       Date:  2009-10       Impact factor: 2.500

2.  Analysis of mutational spectra by denaturing capillary electrophoresis.

Authors:  Per O Ekstrøm; Konstantin Khrapko; Xiao-Cheng Li-Sucholeiki; Ian W Hunter; William G Thilly
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

Review 3.  Mutator/Hypermutable fetal/juvenile metakaryotic stem cells and human colorectal carcinogenesis.

Authors:  Lohith G Kini; Pablo Herrero-Jimenez; Tushar Kamath; Jayodita Sanghvi; Efren Gutierrez; David Hensle; John Kogel; Rebecca Kusko; Karl Rexer; Ray Kurzweil; Paulo Refinetti; Stephan Morgenthaler; Vera V Koledova; Elena V Gostjeva; William G Thilly
Journal:  Front Oncol       Date:  2013-10-29       Impact factor: 6.244

4.  Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.

Authors:  Barbara L Parsons; Karen L McKim; Meagan B Myers
Journal:  Environ Mol Mutagen       Date:  2017-07-29       Impact factor: 3.216

Review 5.  Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk.

Authors:  Kelly L Harris; Meagan B Myers; Karen L McKim; Rosalie K Elespuru; Barbara L Parsons
Journal:  Environ Mol Mutagen       Date:  2019-10-06       Impact factor: 3.216

6.  Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.

Authors:  Daniel J Craig; Thomas Morrison; Sadik A Khuder; Erin L Crawford; Leihong Wu; Joshua Xu; Thomas M Blomquist; James C Willey
Journal:  BMC Cancer       Date:  2019-11-11       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.